Drug Type Fusion protein |
Synonyms NPT 189, NPT189 |
Target |
Action modulators, inhibitors |
Mechanism APP modulators(Beta amyloid A4 protein modulators), TAU inhibitors(Microtubule-associated protein tau inhibitors), α-synuclein inhibitors(Synuclein alpha inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Amyloidosis, Hereditary, Transthyretin-Related | Phase 1 | United States | 30 Jan 2022 | |
| Immunoglobulin Light-Chain Amyloidosis | Phase 1 | United States | 30 Jan 2022 | |
| Amyloidosis | Phase 1 | Netherlands | 24 Jul 2018 |






